Humana Inc. (NYSE:HUM) has earned a consensus recommendation of “Hold” from the twenty-two analysts that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and twelve have issued a buy recommendation on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $242.37.

A number of equities analysts have recently commented on the company. UBS AG reiterated a “neutral” rating and issued a $237.00 target price (up previously from $205.00) on shares of Humana in a report on Wednesday, June 28th. Zacks Investment Research cut Humana from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $223.00 target price (up previously from $200.00) on shares of Humana in a report on Thursday, August 3rd. Jefferies Group LLC reiterated a “hold” rating and issued a $257.00 target price on shares of Humana in a report on Friday. Finally, BidaskClub cut Humana from a “hold” rating to a “sell” rating in a report on Monday, July 31st.

In other Humana news, SVP Brian P. Leclaire sold 4,971 shares of Humana stock in a transaction on Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the completion of the sale, the senior vice president now directly owns 14,258 shares of the company’s stock, valued at approximately $3,421,920. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Heidi S. Margulis sold 1,500 shares of Humana stock in a transaction on Friday, May 26th. The shares were sold at an average price of $231.96, for a total value of $347,940.00. Following the sale, the vice president now directly owns 8,150 shares of the company’s stock, valued at $1,890,474. The disclosure for this sale can be found here. Insiders own 0.80% of the company’s stock.

A number of large investors have recently modified their holdings of HUM. Guardian Life Insurance Co. of America raised its stake in shares of Humana by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 575 shares of the insurance provider’s stock worth $119,000 after buying an additional 4 shares during the period. Independent Portfolio Consultants Inc. raised its stake in shares of Humana by 22.1% in the second quarter. Independent Portfolio Consultants Inc. now owns 519 shares of the insurance provider’s stock worth $125,000 after buying an additional 94 shares during the period. Point72 Asia Hong Kong Ltd purchased a new stake in shares of Humana during the first quarter worth $128,000. Westbourne Investment Advisors Inc. purchased a new stake in shares of Humana during the second quarter worth $205,000. Finally, Hengehold Capital Management LLC purchased a new stake in shares of Humana during the second quarter worth $209,000. 99.66% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/08/08/humana-inc-nysehum-given-consensus-rating-of-hold-by-brokerages.html.

Shares of Humana (NYSE:HUM) opened at 249.62 on Tuesday. Humana has a 12 month low of $163.50 and a 12 month high of $251.79. The company has a market cap of $36.07 billion, a P/E ratio of 20.53 and a beta of 0.91. The firm has a 50-day moving average price of $236.19 and a 200 day moving average price of $220.68.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share for the quarter, beating the consensus estimate of $3.08 by $0.41. The business had revenue of $13.53 billion during the quarter, compared to analysts’ expectations of $13.61 billion. Humana had a return on equity of 15.85% and a net margin of 3.37%. During the same quarter last year, the business posted $2.30 EPS. Equities analysts predict that Humana will post $11.45 earnings per share for the current year.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.